March 20th 2023
Despite failing to meet primary trial endpoints, molnupiravir reduced the length of COVID-19 infection by 4.2 days in vaccinated patients.
FDA Advisory Committee Recommends Approving First-Ever RSV Vaccine
February 28th 2023Pfizer indicates their RSV vaccine candidate, Abrysvo (RSVpreF), to prevent acute respiratory disease and lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 60 years and older by active immunization.
Read More
The Tripledemic as a Precursor to Stakeholder Alignment under the Quintuple Aim
February 8th 2023Infectious disease outbreaks will continue to increase and trying to find strategies to ensure providers are cared for to prevent burnout and shortage staffing is essential if another pandemic arises.
Read More
Overview of the Different Types of Respiratory Infections
Experts provide an overview of the clinical presentations of respiratory infections such as COVID-19, influenza, and respiratory syncytial virus.
Watch
Patient Populations at Greater Risk of Contracting Respiratory Viruses
Tina Tan, MD; Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP; Priya Nori, MD; Jacinda Abdul-Mutakabbir, PharmD; and Kevin Michael Reiter, MD, PA, discuss patient populations that are at greater risk of contracting and suffering from complications related to respiratory viruses.
Watch